Literature DB >> 28865147

Differential regulation of PD-1 and its ligands in allergic asthma.

K Bratke1, L Fritz1, F Nokodian1, K Geißler1, K Garbe1, M Lommatzsch1, J C Virchow1.   

Abstract

BACKGROUND: Targeting PD-1/PD-1 ligand signalling is an established treatment option for cancer. The role of these molecules in allergic asthma has been investigated in several mouse studies yielding conflicting results. However, human studies investigating the expression and regulation of PD-1 and its ligands in allergic inflammation are lacking.
OBJECTIVE: To analyse the expression and regulation of PD-1 and its ligands in human allergic asthma.
METHODS: The well-established human asthma model of segmental allergen challenge (SAC) was used to analyse the regulation of PD-1 and its ligands PD-L1 and PD-L2 on T lymphocytes and dendritic cells by flow cytometry. The impact of immunoglobulin E (IgE)-mediated signalling on PD-L1 expression was analysed on isolated plasmacytoid dendritic cells (pDCs).
RESULTS: PD-1 expression by blood CD4+ T cells was negatively associated with total and specific (against the allergen used for provocation) IgE serum concentrations. Twenty-four hours after SAC, a small decrease in endobronchial PD-1+ CD4+ T cells was accompanied by an increase in PD-L1 expression on endobronchial myeloid dendritic cells (mDCs) and pDCs. The PD-L1 up-regulation on pDCs was not induced by IgE-mediated mechanisms. In contrast, PD-L2 was only detected on endobronchial mDCs and was significantly down-regulated 24 hours after SAC. CONCLUSION AND CLINICAL RELEVANCE: This study shows, for the first time, an association of a low PD-1 expression by circulating CD4+ T cells with high total and specific (against the allergen used for provocation) IgE concentrations in allergic asthma. In addition, we demonstrate a differential regulation of PD-1 ligands on endobronchial DCs after allergen challenge which may favour Th2 inflammation. Therefore, modulating PD-1 ligand-mediated pathways might be a promising target in allergic asthma.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  IgE; T cells; asthma; basic mechanisms; dendritic cells

Mesh:

Substances:

Year:  2017        PMID: 28865147     DOI: 10.1111/cea.13017

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  6 in total

1.  PD-L1 Blockade During Allergen Sensitization Inhibits the Synthesis of Specific Antibodies and Decreases Mast Cell Activation in a Murine Model of Active Cutaneous Anaphylaxis.

Authors:  Rafael Bonamichi-Santos; Marcelo Vivolo Aun; Jorge Kalil; Mariana Concepcion Castells; Pedro Giavina-Bianchi
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

2.  Trichinella spiralis Infection Mitigates Collagen-Induced Arthritis via Programmed Death 1-Mediated Immunomodulation.

Authors:  Yuli Cheng; Xing Zhu; Xiaohuan Wang; Qinghui Zhuang; Xu Huyan; Ximeng Sun; Jingjing Huang; Bin Zhan; Xinping Zhu
Journal:  Front Immunol       Date:  2018-07-26       Impact factor: 7.561

3.  A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.

Authors:  Takayuki Jodai; Chieko Yoshida; Ryo Sato; Yosuke Kakiuchi; Nahoko Sato; Shinji Iyama; Tomoko Kimura; Koichi Saruwatari; Sho Saeki; Hidenori Ichiyasu; Kazuhiko Fujii; Yusuke Tomita
Journal:  Immun Inflamm Dis       Date:  2018-11-21

Review 4.  The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors.

Authors:  Xiao-Hui Jia; Lu-Ying Geng; Pan-Pan Jiang; Hong Xu; Ke-Jun Nan; Yu Yao; Li-Li Jiang; Hong Sun; Tian-Jie Qin; Hui Guo
Journal:  J Exp Clin Cancer Res       Date:  2020-12-14

Review 5.  New Insights into the Role of PD-1 and Its Ligands in Allergic Disease.

Authors:  Miguel Angel Galván Morales; Josaphat Miguel Montero-Vargas; Juan Carlos Vizuet-de-Rueda; Luis M Teran
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 5.923

6.  PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity.

Authors:  Doumet Georges Helou; Pedram Shafiei-Jahani; Richard Lo; Emily Howard; Benjamin P Hurrell; Lauriane Galle-Treger; Jacob D Painter; Gavin Lewis; Pejman Soroosh; Arlene H Sharpe; Omid Akbari
Journal:  Nat Commun       Date:  2020-08-10       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.